Background: Gastric cancer risk evolves over time due to environmental, dietary, and lifestyle changes including Helicobacter pylori (H. pylori) infection and consumption of hot peppers (i.e. capsaicin). H. pylori infection promotes gastric mucosal injury in the early phase of capsaicin exposure. In addition, capsaicin consumption is reported to suppress immune function and increase host susceptibility to microbial infection. This relationship suggests a need to investigate the mechanism of how both H. pylori infection and capsaicin contribute to gastric inflammation and lead to gastric cancer. No previous experimental animal models have been developed to study this dual association. Here we developed a series of mouse models that progress from chronic gastritis to gastric cancer.
Introduction
The Centers for Disease Control and Prevention estimates that roughly two-thirds of adults harbor Helicobacter pylori ( H. pylori), a bacterium that colonizes the stomach and duodenum. Without treatment, H. pylori infection is a known risk factor for gastrointestinal illnesses like chronic gastritis, peptic ulcers, and stomach cancer. In 2001, an epidemiologic study demonstrated that patients infected with H. pylori were nearly six times more likely to develop gastric cancer compared to uninfected people 1 . Other gastric cancer risk factors include dietary and lifestyle practices including capsaicin consumption, stress levels, and ingestion of inflammatory foods or beverages. In summary, the etiology of gastric cancer is comprised of bacterial variability, along with host genetic and environmental factors; however, the molecular mechanisms governing these factors have not been fully elucidated 2, 3, 4 .
Evidence suggests that H. pylori infection impacts the development and progression of gastric mucosal injury during early capsaicin exposure from hot pepper consumption 5 .
Capsaicin reportedly suppresses immune function and increases host susceptibility to infection 6, 7, 8 . Other data suggest an epidemiological link between stomach cancer incidence and chili pepper-rich diets 5, 9 . Ultimately, capsaicin's role in carcinogenesis remains controversial. Additionally, most studies have not considered H. pylori infection to be a coinciding or modifying component during gastric cancer development. This unidentified interplay between H. pylori infection and other agents may be critical to the initiation and persistence of gastric inflammation, as well as the development of gastric cancer. Here we explore the combined effect of H. pylori infection and capsaicin exposure on the development of gastritis and gastric carcinogenesis, as well as possible antiinflammatory regimens for disease prevention. The selected anti-inflammatory agent, DFMO (2-difluoromethylornithine), reportedly alters immune populations within the tumor microenvironment and inhibits tumor growth by increasing CD8 + infiltration 10, 11 . Despite its chemopreventive potential, the anti-inflammatory and anti-cancer effects of DFMO against gastritis and gastric cancer are unknown.
Previous studies have not adequately addressed H. pylori infection as a concurring or modifying factor for gastric cancer risk. Additionally, the role of capsaicin consumption in the development of gastritis and gastric cancer has not been experimentally elucidated before now. Here, we explore the combined effect of H. pylori infection and capsaicin consumption on the development of gastritis and later gastric cancer. Lastly, we highlight DFMO as an anti-inflammatory treatment against gastritis and as a preventative measure against gastric carcinogenesis.
Results

Capsaicin and pylori infection induce gastritis leading to gastric cancer
To investigate the role of capsaicin consumption in the progression of H. pylori-associated gastric cancer, we developed a mouse model treated with a combination of capsaicin and H. pylori infection to induce gastritis, leading to gastric cancer (Fig. 1a ). Macroscopic morphometric analysis revealed that capsaicin consumption induced gastric inflammation 5 (at 32 weeks) as the initiating process, which led to tumor development (at 52 weeks) in the stomach of mice with H. pylori infection (Fig. 1b ). Tumor growth in mice treated with both capsaicin and H. pylori confirmed the role of a combination of capsaicin and H. pylori in gastric tumorigenesis. Macroscopic analysis of tumor area revealed development of tumors only in mice treated with both H. pylori and capsaicin (30.26 ± 7.017 mm 2 ; p < 0.0001; Fig. 1c ). Mice treated with a combination of H. pylori and capsaicin showed significantly lower body weight compared to untreated mice ( Fig. 1d ). Overall, these results indicated that H. pylori and capsaicin together caused a progressive shift from gastritis to gastric cancer. These results provided experimental animal evidence showing the combined effect of capsaicin and H. pylori infection on the development of gastric cancer. Histological analysis also showed multifocal elongation of the gastric pits, glandular atrophy, and a significant reduction in the glandular zone in atrophic foci. These changes were significantly less in mice treated with capsaicin and infected with H. pylori exhibiting tumors (0.2 ± 0.2; p < 0.0001), compared to mice treated with only capsaicin (2.60 ± 0.24; p = 0.02) or infected with H. pylori only (1.0 ± 0.316; p = 0.0002;
Mice treated with capsaicin and pylori exhibit increased gastric atrophy and accelerated tumor growth Histologic analysis revealed significant glandular atrophy in the fundus of mice at 32 weeks of a combination treatment of capsaicin and H. pylori compared with untreated mice or mice treated only with capsaicin or H. pylori (Fig. 2 ). Dual treatment resulted in reduction of parietal cell components, especially parietal and chief cells, which were replaced by gastric mucus-producing cells. Pepsinogen I and II, gastrin, somatostatin (gastric endocrine regulators), and H+ /K+ ATPase (parietal and chief cells) showed 6 substantially lowered expression in mice exhibiting gastric tumorigenesis compared with untreated mice or mice treated singularly (0.264 ± 0.09; p < 0.0001; Fig. 2a-f ). Gastrin, somatostatin, and H+/K+ ATPase are required for normal gastric mucosal development and parietal cell activation 12, 13 . In mice exhibiting carcinogenesis, these biomolecules were almost completely ablated. As a result, a combination of capsaicin and H. pylori directly accelerated loss of differentiated epithelial cell types, leading to chronic atrophic gastritis and eventually to gastric tumorigenesis. The combination treatment shifts gastric tissue to a tumor phenotype with increased numbers of inflammatory cells found in the tumor gastric mucosa. This observation suggests that H. pylori or capsaicin alone is not enough to cause gastric tumorigenesis and that a combination is required to trigger the formation of submucosal glands and invasion of tumor cells.
Diminished expression of tumor suppressor genes coincides with accelerated tumorigenesis
The effect of a combination of capsaicin and H. pylori is associated with increased tumor progression due to substantially reduced expression of several gastric tumor suppressor genes (TSGs), including Tff1 by qPCR (0.273 ± 0.120), Tff2 (0.126 ± 0.078), Gkn1 (0.143 ± 0.045) and Gkn2 (0.172 ± 0.060) in the group of mice that developed tumors compared to other groups (p < 0.0001; Fig. 3a-d ). Loss of these gastric-specific TSGs promotes tumorigenesis 14, 15, 16 . Tff1 and Tff2 genes are upstream regulators of gastrokine (Gkn) gene expression. Therefore, loss of Tff1 or Tff2 expression could lead to tumor growth 17 .
These genes were substantially downregulated in mice exhibiting gastric tumors, and the reduction was associated with the combined treatment of capsaicin and H. pylori infection.
Overall, inhibition of Tff1, Tff2, Gkn1, and Gkn2 is known to be associated with tumorigenesis 17,18 . 7 Mice administered capsaicin and pylori display increased gastric tissue damage The extent of gastric tissue damage was evaluated as well. We found that mice treated simultaneously with capsaicin and H. pylori exhibited tumor development. These mice 
Capsaicin dose in mice resembles human capsaicin consumption and mimics stage-dependent gastric cancer development
To apply our observations to humans, we optimized the mice's intake to reflect human intake to determine the dose-dependent (0.01-0.5% or 0.05-2.6g/kg/day) effect of capsaicin. Mice treated with both H. pylori and capsaicin developed gastritis, leading eventually to cancer. To confirm this relationship in mice and to establish its relevance in humans, we conducted toxicity experiments in mice and optimized the capsaicin amount to determine its dose-dependent (0.01-0.5% or 0.05-2.6g/kg/day) effect. Mice treated with a combination of H. pylori infection and capsaicin (at a dose greater than 0.06% or 0.312g/kg/day but less than 0.05% or 0.26g/kg/day), which is relevance to human dose of capsaicin (0.021-0.025-g/kg/day) induced a non-toxic effect. Notably, a dose greater than 0.05% or 0.26g/kg/day induced significant toxicity and severe gastric inflammation. In contrast, a dose less than 0.05% or 0.26g/kg/day did not cause any toxic effect or any significant gastric inflammation in mice ( Supplementary Tables 1 and 2) . As a result, we selected a non-toxic, dose of 0.05% or 0.26g/kg/day 2 . These results suggest that capsaicin dosage contributes considerably to the development of gastric inflammation and carcinogenesis.
We also examined capsaicin intake, metabolism, and excretion. We found a high blood assimilation of capsaicin in mice treated with capsaicin and H. pylori (0.002 ± 0.0004 g/kg/day) compared to mice treated only with capsaicin (0.002 ± 0.0002 g/kg/day). This observation corresponded with low urine dissimilation of capsaicin in the gastric tumor group (0.0003 ± 0.00001 g/kg/day) compared to the group treated with only capsaicin (0.0006 ± 0.0001 g/kg/day; Fig. 6a ). Similar results were found in human samples; gastric 9 cancer patients (0.003 ± 0.0002 g/kg/day) and chronic gastritis patients (0.001 ± 0.0002 g/kg/day) showed high levels of capsaicin blood assimilation compared to healthy subjects (0.0005 ± 0.0001g/kg/day; p < 0.0001; Fig. 6b ). These results also confirmed the role of capsaicin consumption in the development of physiological abnormalities and gastric cancer. High levels of capsaicin metabolites in urine following capsaicin consumption may be a sign of gastric tumor development as well. The risk for capsaicin-associated cancer is influenced by the expression of capsaicin metabolizing enzymes, such as 16hydroxycapsaicin, 17-hydroxycapsaicin, and 16, 17-dehydrocapsaicin, vanillylamine, and vanillin, which increase the risk for cancers. As a result, propose that capsaicin is a potential carcinogen 22 23 . Ultimately, we developed a mouse model that utilizes a capsaicin dosage relevant to human capsaicin intake. With this model, gastric tumorigenesis is induced without toxicity in peripheral organs. As a result, this mouse model was used to study the effect of capsaicin and its metabolites on the development of gastric cancer.
Capsaicin-treated and pylori-infected mouse tumors show increased proinflammatory cell infiltration
Gastric inflammation leads to gastric tumor development. In our mouse model, the number of pro-inflammatory cell types was significantly increased (i.e., leukocyte infiltration), as observed by the numbers of activated macrophages (F4/80 positive) and neutrophils (myeloperoxidases, MPO) in mice exhibiting gastric tumors (0.746 ± 0.041 and 0.721 ± 0.064, respectively), compared to untreated mice or mice treated with only capsaicin or H. pylori ( p < 0.0001; Supplementary Fig. 2a-b ). Due to increased immunocyte infiltration, we analyzed several inflammatory-related chemokines and cytokines at the mRNA and protein (secretion) levels by using a customized multiplex magnetic bead array. In mice treated with capsaicin and H. pylori, gastric tumorigenesis was associated with augmented Th1 (IFN-γ, IL-1β, and GM-CSF) and Th2 (IL-10, IL-6, IL-13) cytokine expression (p < 0.001; Fig. 7a -l). In particular, the pro-inflammatory cytokines IL-6 and IFN-γ showed high and low expression in mice with gastric cancer induced by treatment with capsaicin and H. pylori, respectively. Overall, H. pylori infection and capsaicin consumption produced great sensitivity and specificity towards IL-6 and IFN-γ expression. As a result, IL-6 and IFN-γ cytokines may play a critical role in the development of gastric inflammation and later gastric cancer.
DFMO prevents pylori-and capsaicin-induced gastric cancer
We determined the role of IL-6 and IFN-γ in gastric cancer prevention using the antiinflammatory agent DFMO (scheme illustrated in Fig. 8h ). We administered capsaicin and H. pylori to mice followed by DFMO treatment. Macroscopic morphometric analysis revealed that DFMO (100 and 200 mg/kg) inhibited gastric inflammation in a dosedependent manner and prevented gastric tumorigenesis ( Fig. 8a, b ). The antiinflammatory potential of DFMO against gastritis and therefore against gastric cancer was evaluated by analyzing IL-6 and IFN-γ status. We observed a significant dose-dependent decrease and increase in the pro-inflammatory cytokine IL-6 and IFN-γ level for DFMOtreated mice compared to untreated mice exhibiting gastritis and to H. pylori-eradicated mice (p < 0.0001; Fig. 8c, d) , respectively. In contrast, COX-1 and COX-2 expression was also substantially reduced (p < 0.001; Fig. 8e , f). Histological analysis also showed multifocal elongation of the gastric pits, glandular atrophy, and a significant reduction in the glandular zone in atrophic foci. These changes were significant in mice treated with capsaicin and infected with H. pylori exhibiting gastric inflammation (2.800 ± 0.200), compared to mice treated with DFMO (200 mg/kg; 1.400 ± 0.244) or untreated (0.6 ± 0.245; p = 0.002; Supplementary Fig. 3a-d ). DFMO-treated mice (100 mg/kg or 200 mg/kg) showed significantly higher body weight compared to mice treated with a combination of capsaicin and H. pylori infection (Fig. 2g ). This result suggests that DFMO may prevent gastric tumorigenesis induced by a combination of capsaicin consumption and H. pylori infection. DFMO appears to act as an anti-inflammatory agent to prevent capsaicin- We propose that H. pylori regulates pro-inflammatory cytokine production and release of IL-6, IFN-γ, IL-17A, IL-1β, IL-27, and TNF-α. This cytokine release causes gastric tissue damage leading to activation of inflammatory cancer signaling pathways (Fig. 7) . The outcome of IL-6 stimulation suggests that pre-existing gastric immunopathology accelerates the loss of differentiated epithelial cell types, leading to profound glandular atrophy and gastric tumorigenesis. In fact, IL-6 stimulation with IFN-γ inhibition may promote the shift from gastric inflammation to gastric carcinogenesis in mice administered both capsaicin and H. pylori (Fig. 7) . As a result, IL-6 inhibitors can serve as a therapy against gastric cancer, in addition to lowered capsaicin intake and pathogen clearance. Gastritis patients with high IL-6 levels could also benefit from IL-6 inhibition as a preventive measure against gastric carcinogenesis ( Fig. 7) . However, loss of Tff1 and Tff2 promotes increased gastric inflammation and accelerates fundic atrophy with significant loss of parietal and chief cell lineages (Fig. 3) . This finding provides a mechanism for capsaicin-associated gastric cancer cell proliferation 18 .
Tumorigenesis in
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Our data suggest that combined capsaicin exposure and H. pylori infection modulate and imbalance Th1 and Th2 cytokine levels, leading to mucosal inflammation, inhibition of gastric acid secretion, and induction of fundic atrophy. Tumorigenesis in capsaicin-and H. pylori-treated mice was associated with augmented Th1 cytokine release, particularly IL-6, along with attenuated Th2 cytokine expression. Th1 cytokines like IL-6 promote chronic atrophic gastritis and predisposition to tumorigenesis through inhibition of gastrin and somatostatin, as indicated earlier (Fig. 7) . In combination, capsaicin and H. pylori provide a gastric cancer development mechanism in which local immune responses modulate and decrease essential gastric hormones.
Here, the selected anti-inflammatory agent, DFMO 
Conclusion.
This study describes the mechanisms governing the induction and progression of chronic gastritis to gastric cancer under the inflammatory triggers of H. pylori infection and capsaicin exposure. This study also proposes DFMO treatment to prevent gastric cancer through pro-inflammatory IL-6 cytokine inhibition, resulting in diminished gastric inflammation. This study is the first to provide experimental animal evidence showing gastric cancer prevention by DFMO treatment in mice with capsaicin consumption and H. pylori infection. In the future, these mouse models can also facilitate further studies into the molecular mechanisms of chronic gastritis and gastric cancer. Mice were administered a suspension of DFMO by gavage 3 times a week for 2 months. A toxicity assay was performed to optimize the amount for consumption. Mice (n = 10) were administered different amounts of capsaicin (0.01-0.5% or 0.05-2.6 g/kg/day) up to 3 weeks and mouse survival rate was analyzed.
Methods
Preparation of H . p y l o r i s t r a i n s
Gastric sample preparation
Mice were euthanized and their stomachs excised and gently rinsed with cold saline. For gastric tumor phenotype analyses, stomachs were opened along the greater curvature and spread out on a polypropylene sheet (Jiangsu Jiangyin Jinfeng Textile Co., Jiangsu, China).
The area (mm 2 ) of the mucosal erosive lesions was measured and tumors were macroscopically identified in the gastric mucosae by micro-dissection of gastric tumor tissue. The anterior wall of the pyloric antrum contains the pyloric glands and gastric epithelial cells were cut into several linear strips for quantitative enzyme activity, DNA, RNA, protein, and histological analyses. Other peripheral organs were also collected, including brain, lung, liver, kidney, spleen, colon, and heart, in order to analyze by H&E staining the toxic effect of capsaicin consumption.
Patients And Gastroendoscopy
All gastric patients were subjected to gastroendoscopy and examination in the Second Co., Henan, China), and streptomycin (1 × 10 5 U/ml; North China Pharmaceutical, Hebei, China). The tissues were divided into 3 parts. One portion was implanted into CB17 SCID mice purchased from Beijing Vital River Laboratory (Beijing, China). The second portion was fixed in 10% formalin, and the third portion was used for protein extraction. The mice were anesthetized using 0.3 ml of 0.4% (w/v) pentobarbital sodium (150 µl/10 g;
Mouse-derived Xenograft Model
Sinopharm Chemical Reagent, Guangdong, China) for every 20 g of body weight. Then mice were subcutaneously implanted with tissues weighing 0.10-0.12 g and measuring ~ 20 3 mm. Animals were monitored periodically for their weight and tumor growth. A second passage was performed and the same protocol was followed as described above.
Statistical analysis
The experiments were randomized and investigators were blinded to histological examination during all experiments. All statistical analyses were performed using 
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Figure 4
The level of tissue damage in gastric mucosa from gastric disease mouse models.
Biochemical activity of a) LPO, b) carbonyl, c) catalase, d) MPO, and e) MDA in mice. Mice exhibiting gastritis or tumorigenesis show higher biochemical activity of these parameters compared to mice treated with capsaicin or H. pylori only (n = 5/cohort). 
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